Master Rollover Protocol for Continued Safety Assessment of Study Drug
Sponsor
Eli Lilly and Company (Industry)
Overall Status
Available
CT.gov ID
NCT02632994
Collaborator
(none)
3
Study Details
Study Description
Brief Summary
This study is for patients who have participated in a previous study and who continue to receive benefit to have continued access to study drug and/or treatment.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
Study Design
Study Type:
Expanded Access
Official Title:
Master Rollover Protocol for Continued Safety Assessment of Study Drug
Outcome Measures
Primary Outcome Measures
Eligibility Criteria
Criteria
Ages Eligible for Study:
18 Years
and Older
Sexes Eligible for Study:
All
Inclusion Criteria:
- To be eligible patients must be currently receiving benefit in a concluded Lilly study for a compound that has opened an addendum in the continued access protocol.
Exclusion Criteria:
- Patients must not be concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | UCLA Medical Center | Torrance | California | United States | 90505 |
| 2 | Fort Wayne Oncology & Hematology | Fort Wayne | Indiana | United States | 46804 |
| 3 | Sarah Cannon Cancer Center | Nashville | Tennessee | United States | 37203 |
Sponsors and Collaborators
- Eli Lilly and Company
Investigators
- Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT -5 hours, EST), Eli Lilly and Company
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
Eli Lilly and Company
ClinicalTrials.gov Identifier:
NCT02632994
Other Study ID Numbers:
- 16161
- I8I-MC-JYAA
First Posted:
Dec 17, 2015
Last Update Posted:
Aug 18, 2022
Last Verified:
Aug 15, 2022